Rene Coulombe

Laval, QC H7V4A7, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.

Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.

Journal: Journal of medicinal chemistry
Published: December 29, 2023

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Journal: ACS medicinal chemistry letters
Published: May 11, 2016

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Journal: Antimicrobial agents and chemotherapy
Published: March 26, 2014

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Journal: ACS medicinal chemistry letters
Published: March 15, 2014

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Journal: Journal of medicinal chemistry
Published: January 29, 2014

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Journal: ACS medicinal chemistry letters
Published: January 03, 2014

Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).

Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127).

Journal: Journal of medicinal chemistry
Published: October 29, 2013

Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity.

Enantiomeric atropisomers inhibit HCV polymerase and/or HIV matrix: characterizing hindered bond rotations and target selectivity.

Journal: Journal of medicinal chemistry
Published: September 13, 2013

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

Journal: Journal of medicinal chemistry
Published: August 08, 2013

Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.

Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay.

Journal: Bioorganic & medicinal chemistry letters
Published: July 25, 2013

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

Journal: Journal of medicinal chemistry
Published: June 19, 2013

Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

Journal: Journal of medicinal chemistry
Published: June 05, 2013
Showing 1-12 of 18

Last Updated: 09/26/2026